Distalmotion raises $150M to accelerate FDA approval and clinical experience
Distalmotion announced today the first closing of its USD 150 million financing. This significant fundraise reinforces the confidence of its existing investors led by Revival Healthcare Capital.
Dexter, Distalmotion’s robotic platform, is in day-to-day clinical use in Europe, successfully treating patients across a multitude of complex and high-volume procedures in general surgery, gynecology, urology. This funding will enable the way for US Food and Drug Administration (FDA) approval and to continue acceleration of clinical experience in Europe.
“Dexter allows for ‘on-demand robotics’ and gives surgeons access to the benefits of both robotic and laparoscopic surgery, enabling best-in-class minimally invasive care for the patients,” explained Distalmotion CEO Michael Friedrich. “Surgeons can choose to operate entire procedures robotically, or they can leverage the ability to easily switch between the robotic and laparoscopic modalities to perform specialized tasks such as stapling with their preferred and trusted instruments. Surgeons are therefore empowered with choice and control.”
Dexter makes robotic surgery more accessible, enabling a wider adoption of robotic surgery. Dexter is easily integrated into clinical practice – it requires no additional infrastructure, it fits into every clinical setting, and it is mobile allowing for easy sharing across departments. This empowers institutions to scale robotics programs across surgical disciplines to offer more patients an enhanced standard of care in both hospital and surgery center settings.
“Dexter delivers what surgeons need most for when it matters most. It provides advanced dexterity for complex surgical steps such as suturing, dissection and working in confined spaces” said Prof. Dieter Hahnloser, head of colorectal surgery at Lausanne University Hospital who performed the first general surgery procedure with Dexter in 2021. “Dexter’s open platform allows surgeons to choose the best in-class tools and technology for each step of the procedure. It is compatible with all 3D laparoscopes which allows surgeons to leverage current and future imaging innovations.”
“This latest financing sets the stage for Distalmotion to accelerate our mission of expanding the adoption of Dexter to hospitals worldwide,” said Rick Anderson, Chairman of Revival and Chairman of Distalmotion. “We are very proud of our global leadership team’s accomplishment to bring Distalmotion’s technology to the market and to set the stage for the company’s entry into the US market”.
For more commentary see the press release – Distalmotion raises $150M to accelerate FDA approval and clinical experience